FBRX News and Press, Forte Biosciences Inc. From 05/19/23

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compen...

2023-05-15 17:04:01 ET Forte Biosciences press release ( NASDAQ: FBRX ): Q1 GAAP EPS of -$0.32. Forte ended the first quarter 2023 with approximately $35.9 million in cash and cash equivalents. For further details see: Forte Biosciences GAAP EPS of -$0.32

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provided a business update. First Quarter 2023 Business Highlights “We are very pleased with the develop...

2023-04-06 15:53:22 ET Whether you’re trading penny stocks or higher-priced names, you can’t ignore what’s happening in the stock market today. Traders have remained cautiously optimistic following a week’s worth of data and more still to come on Friday when ...

2023-04-03 00:59:15 ET Forte Biosciences press release ( NASDAQ: FBRX ): FY GAAP EPS of -$0.80. Forte ended 2022 with approximately $41.1 million in cash and cash equivalents. For further details see: Forte Biosciences GAAP EPS of -$0.80

-FB-102 Continues to Advance Towards the Clinic Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update. “FB-102 continues to progress ...

-Addition of Mr. David Gryska Further Strengthens Forte Board of Directors Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors. Mr. Gryska was previously the Chief Fin...

Forte Biosciences press release ( NASDAQ: FBRX ): Q3 GAAP EPS of -$0.18 misses by $0.03 . “Forte is making excellent progress with its lead program FB-102, which is a direct result of the team’s hard work and diligent efforts. FB-102 holds significant pot...

-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Boa...

-FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications - -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 ...